| Selecting patients with cisplatin-resistant germ cell tumors for high- dose chemotherapy |
| RJ Motzer |
|
JCO Oct 1 1996: 2625–2626.
[PDF]
|
 |
| Interferons as biochemical modulators |
| EC Borden and S Wadler |
|
JCO Oct 1 1996: 2627–2630.
[PDF]
|
|
|
Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support |
| |
BK Margolin, JH Doroshow, C Ahn, V Hamasaki, L Leong, R Morgan, J Raschko, S Shibata, G Somlo, and M Tetef |
| |
JCO Oct 1 1996: 2631–2637.
[Abstract]
[PDF]
|
|
|
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables |
| |
J Beyer, A Kramar, R Mandanas, W Linkesch, A Greinix, JP Droz, JL Pico, A Diehl, C Bokemeyer, HJ Schmoll, CR Nichols, LH Einhorn, and W Siegert |
| |
JCO Oct 1 1996: 2638–2645.
[Abstract]
[PDF]
|
|
|
Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette- Guerin therapy: correlation to clinical outcome |
| |
L Lacombe, G Dalbagni, ZF Zhang, C Cordon-Cardo, WR Fair, HW Herr, and VE Reuter |
| |
JCO Oct 1 1996: 2646–2652.
[Abstract]
[PDF]
|
|
|
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial |
| |
AM Eggermont, H Schraffordt Koops, D Lienard, BB Kroon, AN van Geel, HJ Hoekstra, and FJ Lejeune |
| |
JCO Oct 1 1996: 2653–2665.
[Abstract]
[PDF]
|
|
|
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study |
| |
BF Cole, RD Gelber, JM Kirkwood, A Goldhirsch, E Barylak, and E Borden |
| |
JCO Oct 1 1996: 2666–2673.
[Abstract]
[PDF]
|
|
|
Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer |
| |
FA Greco, R Figlin, M York, L Einhorn, R Schilsky, EM Marshall, SS Buys, MJ Froimtchuk, J Schuller, L Schuchter, M Buyse, L Ritter, A Man, and AK Yap |
| |
JCO Oct 1 1996: 2674–2681.
[Abstract]
[PDF]
|
|
|
Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group |
| |
PA Kosmidis, N Tsavaris, D Skarlos, D Theocharis, E Samantas, N Pavlidis, E Briassoulis, and G Fountzilas |
| |
JCO Oct 1 1996: 2682–2687.
[Abstract]
[PDF]
|
|
|
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer |
| |
P Canal, C Gay, A Dezeuze, JY Douillard, R Bugat, R Brunet, A Adenis, P Herait, F Lokiec, and A Mathieu-Boue |
| |
JCO Oct 1 1996: 2688–2695.
[Abstract]
[PDF]
|
|
|
p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases |
| |
C Belluco, JG Guillem, N Kemeny, Y Huang, D Klimstra, MF Berger, and AM Cohen |
| |
JCO Oct 1 1996: 2696–2701.
[Abstract]
[PDF]
|
|
|
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases |
| |
C Carlomagno, F Perrone, C Gallo, M De Laurentiis, R Lauria, A Morabito, G Pettinato, L Panico, A D'Antonio, AR Bianco, and S De Placido |
| |
JCO Oct 1 1996: 2702–2708.
[Abstract]
[PDF]
|
|
|
Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study |
| |
D Perrault, EA Eisenhauer, KI Pritchard, L Panasci, B Norris, T Vandenberg, and B Fisher |
| |
JCO Oct 1 1996: 2709–2712.
[Abstract]
[PDF]
|
|
|
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer |
| |
FA Holmes, T Madden, RA Newman, V Valero, RL Theriault, G Fraschini, RS Walters, DJ Booser, AU Buzdar, J Willey, and GN Hortobagyi |
| |
JCO Oct 1 1996: 2713–2721.
[Abstract]
[PDF]
|
|
|
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience |
| |
E Diamandidou, AU Buzdar, TL Smith, D Frye, M Witjaksono, and GN Hortobagyi |
| |
JCO Oct 1 1996: 2722–2730.
[Abstract]
[PDF]
|
|
|
Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group |
| |
KI Pritchard, AH Paterson, NA Paul, B Zee, S Fine, and J Pater |
| |
JCO Oct 1 1996: 2731–2737.
[Abstract]
[PDF]
|
|
|
Annual hazard rates of recurrence for breast cancer after primary therapy |
| |
T Saphner, DC Tormey, and R Gray |
| |
JCO Oct 1 1996: 2738–2746.
[Abstract]
[PDF]
|
|
|
Randomized trial of a psychologic distress screening program after breast cancer: effects on quality of life |
| |
E Maunsell, J Brisson, L Deschenes, and N Frasure-Smith |
| |
JCO Oct 1 1996: 2747–2755.
[Abstract]
[PDF]
|
|
|
The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study |
| |
MA Sprangers, M Groenvold, JI Arraras, J Franklin, A te Velde, M Muller, L Franzini, A Williams, HC de Haes, P Hopwood, A Cull, and NK Aaronson |
| |
JCO Oct 1 1996: 2756–2768.
[Abstract]
[PDF]
|
|
|
Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors |
| |
GJ Rustin, ES Newlands, JM Lutz, L Holden, KD Bagshawe, JG Hiscox, M Foskett, S Fuller, and D Short |
| |
JCO Oct 1 1996: 2769–2773.
[Abstract]
[PDF]
|
|
|
Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer [published erratum appears in J Clin Oncol 1996 Dec;14(12):3175] |
| |
J Crawford, M O'Rourke, JH Schiller, CH Spiridonidis, S Yanovich, H Ozer, A Langleben, L Hutchins, A Koletsky, G Clamon, S Burman, R White, J Hohneker, and CH] Spiridonitis CH$[corrected to Spiridonidis |
| |
JCO Oct 1 1996: 2774–2784.
[Abstract]
[PDF]
|
|
|
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan |
| |
R Perez-Soler, BS Glisson, JS Lee, FV Fossella, WK Murphy, DM Shin, and WK Hong |
| |
JCO Oct 1 1996: 2785–2790.
[Abstract]
[PDF]
|
|
|
In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation |
| |
UM Saarinen, S Wikstrom, A Makipernaa, M Lanning, M Perkkio, L Hovi, J Rapola, and H Sariola |
| |
JCO Oct 1 1996: 2791–2802.
[Abstract]
[PDF]
|
|
|
Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia |
| |
N Winick, JJ Shuster, WP Bowman, M Borowitz, A Farrow, D Jacaruso, GR Buchanan, and BA Kamen |
| |
JCO Oct 1 1996: 2803–2811.
[Abstract]
[PDF]
|
|
|
Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Munster Relapse Study Group |
| |
C Buhrer, R Hartmann, R Fengler, B Rath, M Schrappe, G Janka-Schaub, and G Henze |
| |
JCO Oct 1 1996: 2812–2817.
[Abstract]
[PDF]
|
|
|
Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas |
| |
JF Kuttesch, Jr, LH Wexler, RB Marcus, D Fairclough, L Weaver-McClure, M White, L Mao, TF Delaney, CB Pratt, ME Horowitz, and LE Kun |
| |
JCO Oct 1 1996: 2818–2825.
[Abstract]
[PDF]
|
|
|
Neuropsychologic effects of chemotherapy on children with cancer: a longitudinal study |
| |
DR Copeland, BD Moore, III, DJ Francis, N Jaffe, and SJ Culbert |
| |
JCO Oct 1 1996: 2826–2835.
[Abstract]
[PDF]
|
|
|
Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients |
| |
F De Conno, L Groff, C Brunelli, E Zecca, V Ventafridda, and C Ripamonti |
| |
JCO Oct 1 1996: 2836–2842.
[Abstract]
[PDF]
|
|
|
Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology |
| |
|
| |
JCO Oct 1 1996: 2843–2877.
[Abstract]
[PDF]
|
|
| The future of cancer research and the role of the National Cancer Institute |
| RD Klausner |
|
JCO Oct 1 1996: 2878–2883.
[PDF]
|
|
| Dexrazoxane for protection against cardiotoxic effects of anthracyclines |
| M Sehested, B Holm, and PB Jensen |
|
JCO Oct 1 1996: 2884a.
[PDF]
|
|
| Optimal management of residual mass after chemotherapy in advanced seminoma: there is time for everything |
| S Culine and JP Droz |
|
JCO Oct 1 1996: 2884b–2885.
[PDF]
|
|
| Perioperative chemotherapy versus adjuvant hormonal therapy in breast cancer: claimed benefits |
| AY Rostom, A Ezzat, and F Zwaan |
|
JCO Oct 1 1996: 2885–2886.
[PDF]
|
|
| Response to commentary on endometrial cancer deaths in tamoxifen- treated breast cancer patients |
| JS Patterson, PV Plourde, and A Milbauer |
|
JCO Oct 1 1996: 2886–2887.
[PDF]
|
|
| Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy |
| MJ O'Connell, MJ Kahn, C Erlichman, RM Goldberg, and LE Shepherd |
|
JCO Oct 1 1996: 2887a.
[PDF]
|
|
| Funerals |
| AI Neugut |
|
JCO Oct 1 1996: 2887b–2888.
[PDF]
|
|
